Purpose: We previously reported unfavorable locoregional control with limited field postoperative radiotherapy for head and neck squamous cell carcinoma patients and thus revised the strategy to cover the whole neck. Head and neck squamous cell carcinoma Patients' outcomes were retrospectively analyzed to compare the efficacy of two treatments. Material and methods: Before 2010, the clinical target volume covered the tumor bed and/or involved the neck region. Since 2011, whole-neck irradiation was planned. Univariate analysis, multivariate analysis, and propensity score matching were performed. The study included 275 patients: 186 received limited field postoperative radiotherapy and 89 received whole-neck postoperative radiotherapy. The median follow-up time for the entire cohort was 40.8 months.
Introduction
The prognosis of locally advanced head and neck squamous cell carcinoma (HNSCC) remains poor. Since early recognition of the benefit of surgery combined with postoperative radiotherapy (PORT) at the MD Anderson Cancer Center, PORT has become a standard treatment for HNSCC with pathological high-risk features (1) . Although there have been no large randomized trials of surgery with and without PORT for HNSCC, two small trials supported the survival benefit of PORT (2, 3) .
Bilateral neck irradiation is the standard approach for most cases of advanced HNSCC, especially when node-positive (4, 5) . However, the details of PORT for HNSCC, such as a definition of the target volume and dose prescription, vary with the clinical and pathological findings as well as the primary site (5) . Physicians sometimes face a therapeutic dilemma in patients with HNSCC after surgery because a large area treated by PORT is associated with a high incidence of toxicity (6) . The Radiation Therapy Oncology Group trial #9501 (RTOG#9501) reported that the rate of late adverse events greater than Grade 3 were 17% and 21% in the PORT group and the PORT plus chemotherapy group, respectively (7) .
To reduce the incidence of adverse events, the head and neck surgeons and radiation oncologists of our hospital adapted limited field (LF)-PORT for advanced HNSCC according to the pathological risk features. However, locoregional control (LRC) with LF-PORT was insufficient in spite of the low incidences of acute and late toxicities in a previous report (8) . Thus, after 2011, the strategy for LF-PORT was changed to whole neck (WN)-PORT to improve LRC and patient survival. Supplementary Fig. 1 shows the timeline of historical development of treatments in our institution. To our knowledge, no study has analyzed the clinical outcomes regarding the radiation fields of PORT for advanced HNSCC. Because of the absence of randomized controlled clinical trial data, a propensity score matching (PSM) was conducted as an alternative method to identify differences in patient outcomes between treatment groups (9, 10) .
The aims of the current study were to compare the efficacy and toxicity of two different radiation strategies (i.e. LF-PORT and WN-PORT) in single institution series using PSM analysis and to test the hypothesis that the use of WN-PORT can reduce the incidence of locoregional recurrence (LRR) and improve patient survival.
Material and methods

Patient population
From 2000 to 2014, data from 296 patients with HNSCC who underwent PORT with curative intent at our hospital were retrospectively reviewed. The study cohort was limited to patients with oral, oropharyngeal, hypopharyngeal and laryngeal cancers, while those with cancers of the nasal and paranasal cavities or unknown primary cancer were excluded because the rate of cervical lymph node metastases is generally low in nasal and paranasal cavity cancer. WN-PORT was applied for all patients with unknown primary cancer. PORT was administered to patients with pathological features of a positive/close surgical margin, the presence of extracapsular extension (ECE) or multiple lymph node metastases. Also, patients with residual tumors and a history of radiotherapy for prior head and neck cancers were excluded. The study cohort included no patient with active double cancer at the start of treatment. The inclusion and exclusion criteria are summarized in Supplementary Fig. 2 .
Before surgery, each patient was evaluated by computed tomography (CT) and/or magnetic resonance imaging (MRI) and endoscopy of the head and neck. Positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (FDG-PET/CT) was performed when necessary. Classification and staging of the primary tumor sites were performed according to version 7 of the Union for International Cancer Control guidelines. Staging was based on pathological findings according to the edition corresponding to the year of diagnosis. Between editions, no changes were made to nodal classification, but T4a and T4b were combined as T4 for analysis. Cases of secondary cervical lymph node metastasis were categorized as T0 for analysis. High risk was defined as the presence of a positive/close margin and/ or ECE. Intermediate risk was defined as the presence of multiple lymph node metastases. These high and intermediate risks were further considered as major risks. Although we showed the results of the entire cohort including T0 and second primary cancer (Table 1) , we conducted the additional analysis with the cohort excluded T0 and second primary cancer from the original cohort (Supplementary  Tables 1 and 2 , Supplementary Fig. 3 ).
Target volume, dose prescription and treatment planning
The target of LF-PORT was defined as follows: the prophylactic clinical target volume of LF (CTV pro-lf ) covered the tumor bed without the lymph node region for close/positive margin cases and only the involved the neck region for multiple node and/or ECE cases. For patients with high-risk feature, a boost field was administered to the clinical target volume of the high-risk area (CTV high-lf ). The planning target volume (PTV) for CTV pro-lf and CTV high-lf was created by circumferential 5-10 mm expansion of the corresponding CTV. However, the margins were modified to avoid critical organs and the spinal cord. The dosage was 40-50 Gy for PTV pro-lf and increased to 50-60 Gy for PTV high-lf .
The target for WN-PORT was defined as follows: the prophylactic clinical target volume of the WN field (CTV pro-wn ) covering the bilateral sites, including Levels II-V, and the supraclavicular and retropharyngeal nodes. In case of oral cavity cancer, Levels Ia and Ib were generally included in CTV pro-wn . For patients with high-risk factors, a boost field was administered to the clinical target volume of the high-risk area (CTV high-wn ). The PTV margin was basically created by 5-mm expansion of CTV pro-wn and CTV high-wn . PTV pro-wn was administered at 40-50 Gy and PTV high-wn was increased to 60-66 Gy. For all patients, PORT was delivered at convention fractions of 1.8-2.0 Gy using a 6-10-MV photon beam. In 2010, postoperative intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost technique was adopted for cases of HNSCC in our hospital. The dosages for PTV pro-wn and PTV high-wn were 50 and 60 Gy, respectively, for which 95% of the PTV received 100% of the prescribed dose (D95 = 100% dose prescription), administered in 30 fractions, using Helical TomoTherapy Hi·Art treatment system (Accuray, Inc., Madison, WI, USA). All patients were immobilized in the supine position with the use of an individually designed facial mask for reproducible positioning. During treatment, patients were examined at least weekly. Once treatment ended, the frequency of follow-up was approximately every month in the first year, every 2 months in the second year, every 4 months in the third year, and every 6 months thereafter. Radiological examinations, including CT, FDG-PET/CT and/or MRI, were performed to assess LRR and distant metastasis at least once every 6 months. Acute and late toxicities were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Outcome measures and statistical analysis
Overall survival (OS) was defined as time from the date of PORT initiation to the date of death or from the date of PORT initiation to the last follow-up (i.e. censor date). Progression-free survival (PFS) was defined as date from PORT initiation to the first confirmed date of any type of progression (local, regional, metastatic or second primary), death or the censor date. LRC was defined as the date from PORT initiation to the first confirmed date of recurrence in the tumor bed or the cervical-node, or the censor date. In-field recurrence was defined as recurrence within the radiation field or the edge of the field. Continuous and categorical variables are presented as medians with ranges and as frequencies with percentages, respectively. Baseline characteristics of the patients were compared between the two strategies using the Wilcoxon-Mann-Whitney test for continuous variables and Fisher's exact test for categorical variables.
OS, PFS and LRC curves were constructed using the KaplanMeier method. The following prognostic factors were assessed by univariate analysis with the use of the log-rank test: sex, age, tumor site, pathological (p)T-stage, pN-stage, margin, ECE, major risk, differentiation, history of surgery for head and neck cancer, radiation dose, radiation strategy, time from surgery to the end of treatment (i.e. package time) and concurrent use of chemotherapy. Risk factors LF-PORT, limited field postoperative radiotherapy; WN-PORT, whole neck postoperative radiotherapy; ECE, extracapsular extension; 3DRT, 3D conformal radiotherapy; IMRT, intensity-modulated radiotherapy. with a probability (P) value of <0.2 by univariate analysis, including major risk, were incorporated into a multivariate analysis with the use of Cox proportional-hazards model. Major risk is clinically important which was strongly correlated to margin and ECE.
After the first analysis of the whole cohort, PSM was performed for patients treated with LF-PORT or WN-PORT to compare the two strategies. Variables of the radiation treatment strategies consisted of the radiation field, dose, modality, and package time. Logistic regression was used to estimate the propensity score (PS) that indicated the probability of receiving LF-PORT vs. WN-PORT on the basis of pretreatment information, which included age, sex, pT-stage, pN-stage, margin, ECE, differentiation, history of surgery for head and neck cancer and use of concurrent chemotherapy. The Hosmer-Lemeshow goodness-of-fit test was used to test the fit of the model for logistic regression. Survival outcomes (OS, PFS and LRC), LRR patterns, and the incidence of adverse events were assessed after matching at a ratio of 1:1 with a caliper width set to 0.05 times the standard deviation of the logit of the PS. In addition, for the matched-pair cohort, the cumulative incidence of LRR in-field and out-of-field were compared using the Gray's test with the cumulative incidence function, which accounted for competing risks in the following: for in-field recurrences, recurrence within the radiation field or at the edge of the field was a competing event; for out-of-field recurrence, recurrence outside of the radiation field was a competing event. All two-sided P values of <0.05 were considered statistically significant. All statistical analyses were performed using R software (version 3.3.2; R Foundation for Statistical Computing, Vienna, Austria).
Ethical considerations
The study protocol was approved by the ethics committee of Aichi Cancer Center Hospital (Permission number 2016_1_318). A retrospective chart review was performed for patients who underwent surgery followed by PORT.
Results
Patient and treatment characteristics
After the exclusion criteria were applied, a total of 275 patients with HNSCC were included in the study: 186 received LF-PORT and 89 received WN-PORT (Table 1 ). The median follow-up duration of the entire cohort was 40.8 (range, 2.3-172) months: 46.9 (range, 2.3-172) months for the LF-PORT group and 27.9 (range, 3.7-65) months for the WN-PORT group. The median follow-up for surviving patients was 54.1 (range, 3.7-172) months.
The median prescribed dose for PTV high-lf and PTV high-wn was 50 and 60 Gy, respectively. Twenty-four patients (25.8%) who received WN-PORT also received IMRT. Ninety-six patients (34.9%) received concurrent chemotherapy: 46 (24.7%) in the LF-PORT group and 50 (56.0%) in the WN-PORT group. The median treatment package time was 70 (range, 43-142) days. Although the median package time of the WN-PORT group was 14 days longer than for the LF-PORT group, a total of 259 (94.2%) patients completed the entire treatment regimen in less than 100 days: 177 (95.2%) in the LF-PORT group and 82 (92.1%) in the WN-PORT group.
OS, PFS and LRC
The median OS period of the entire cohort was 50.5 months. The 2-and 5-year OS rates were 66.8% and 50.9%, respectively. The 2-year PFS and LRC rates of the entire cohort were 49.7% and 70.4%, respectively.
In univariate analysis, prognostic factors of OS were tumor site, pT-stage, pN-stage, ECE, major risk and pathological differentiation, respectively. Although the radiation strategy did not have a significant impact on OS (P = 0.106) and PFS (P = 0.087), LRC was significantly better in the WN-PORT group (hazard ration (HR), 0.38; 95% confidence interval (CI), 0.21-0.67; P < 0.001) ( Table 2 , Fig. 1 ; unadjusted Kaplan-Meier curve).
In multivariate analysis, OS was longer for the WN-PORT group than the LF-PORT group (HR, 0.49; 95% CI, 0.31-0.78; P = 0.003) ( Fig. 1 ; adjusted curve based on the multivariate Cox proportional-hazards model). In multivariate analysis, poorer OS was associated with advanced pT and pN categories, high risk, poorly differentiated tumor, and previous surgery at initial treatment (Table 2) . Advanced pT and pN categories, high risk, poorly differentiated tumor and LF-PORT were also associated with significantly poorer PFS and LRC.
PSM
The Hosmer-Lemeshow goodness-of-fit test confirmed that the logistic regression model to estimate a PS fit the data set well (P = 0.906). PSM resulted in a cohort consisting of 118 patients who were well-matched and divided evenly between the LF-PORT and WN-PORT groups (n = 59; Table 3 ). Patients receiving WN-PORT had better 2-year OS (56.4% vs. 78.1%; HR, 0.410; 95% CI, 0.223-0.751; P = 0.003), 2-year PFS (34.7% vs. 59.8%; HR, 0.523; 95% CI, 0.320-0.856; P = 0.009), and 2-year LRC rates (54.4% vs. 83.2%; HR, 0.279; 95% CI, 0.136-0.573; P < 0.001), respectively. Unadjusted Kaplan-Meier survival curves, adjusted curves based on the Cox proportional-hazards model, and PSmatched Kaplan-Meier survival curves stratified by radiation strategy (LF-PORT vs. WN-PORT) are shown in Fig. 1 .
The LF-PORT group developed significantly more 2-year LRR on both in-field (35.2% vs. 15.1%, P = 0.003) and out-of-field (25.0% vs. 0%, P < 0.001), respectively (Fig. 2) . The LF-PORT group had 20 recurrences from out-of-field; five at the primary site, 12 of regional lymph nodes of the contralateral neck, and three with both. Seventeen patients (85%) had ECE. There was no incidence of out-of-field recurrence in the WN-PORT group.
Toxicities
After PSM, for the LF-PORT and WN-PORT groups, the incidence of Grade 3 or higher late toxicity were as follows: any site (16.7% vs. 6.8%), bone (6.8% vs. 3.4%), pharynx and esophagus (6.8% vs. 3.4%), skin (0% vs. 3.4%) and nerve (0% vs. 3.4%).
Discussion
This study investigated outcomes of two different PORT strategies for patients with HNSCC. The results showed that the recent strategy of WN-PORT was associated with improvements in both LRC and OS, suggesting that extension of the target volume for postoperative HNSCC was sufficiently superior. An inadequate target volume or PORT dose was associated with an increased incidence of regional recurrence. This strategy should be considered after determining the balance between the risk of regional recurrence and expected toxicity from treatment. To date, no randomized controlled trial has compared unilateral to bilateral or limited field to large field of PORT for advanced HNSCC. Thus, the hypothesis of this study was that WN-PORT reduced LRR and improved survival using PSM.
Although the target volume of PORT for HNSCC is defined by the tumor site and pathological risk, irradiation of the bilateral neck is the standard approach for most patients with advanced HNSCC (4,5,11). Vergeer et al. reported that for cases with a positive surgical margin of the primary tumor, elective nodal irradiation should be applied, even if the neck is classified as pN0 (12) . However, several studies reported that ipsilateral PORT was appropriate for selected cases of oral or oropharyngeal carcinoma (13, 14) . In this study, 11 patients with oral or oropharyngeal cancer, graded as pT0-2N0-2b and treated with LF-PORT, had contralateral lymph node metastases, including nine with ECE and 10 with N2b. We previously reported patterns of LF-PORT failure and the risk of contralateral failure (8) . Although it might be reasonable to apply LF-PORT for early stage oral or oropharyngeal cancer without high-risk features, we believe that cases with a higher N stage than N2b and high-risk factor of ECE should receive WN-PORT. In the present study, the use of WN-PORT was associated with a reduced incidence of LRR both in-field and out-of-field in the matched-pair cohort. In-field recurrences included those within and at the margin of the radiation field. A limited CTV of LF-PORT might cause an increase in the incidence of recurrences at the field margin. In the matched-pair cohort, the median dose of LF-PORT was 56 Gy, while that for WN-PORT was 60 Gy. An insufficient dosage for LF-PORT might also increase the incidence of in-field recurrence. Several reports state that the optimal dose of PORT for patients with high-risk features, such as ECE, is greater than 60 Gy (15, 16) . Recurrences from out-of-field at the contralateral neck and primary site are especially concerning for patients with ECE. Therefore, the CTV should include the bed of the primary tumor in cases with a positive margin and ECE.
In this study, univariate and multivariate analyses of the entire cohort detected no significant difference in OS, PFS and LRC between PORT combined chemotherapy (POCRT) and PORT alone. Two randomized trials reported that combined PORT was more effective than PORT alone for patients with high-risk locally advanced HNSCC (7, 17) . In the present analysis, there were considerable biases of selection for POCRT, such as the pathological risk features and general condition of the patient. In addition, this study included several types of chemotherapy regimens administered in various numbers of courses. Although the differences between radiation strategies had greater impacts on patient survival and disease control in this study, concurrent chemotherapy was adopted as the standard care for patients with HNSCC with high-risk features. Our results with WN-PORT with or without chemotherapy were comparable to those in previous reports (Table 4) (7, 11, (17) (18) (19) (20) (21) (22) .
Rosenthal et al. reported that the treatment package time of <100 days was associated with improved tumor control and survival (23) . In our study, more than 94% patients completed the treatment package time in less than 100 days. Although the median duration of WN-PORT was significantly longer than for LF-PORT due to the longer preparation time of IMRT, this difference was not correlated with a decrease in efficacy of WN-PORT, as compared to that of LF-PORT.
RTOG#9501 reported that the incidence of late adverse events of Grade 3 or higher was 21% in the POCRT group (7) . In this series, the incidence of Grade 3 or higher late toxicity of WN-PORT was acceptable (16.7%), in accordance with previous reports. Several studies have reported a lower incidence of toxicity from IMRT with PORT (22, 24, 25) . Ooishi et al. reported an incidence of 8.2% in PORT using IMRT (22) . IMRT enables minimal dose exposure to normal tissue, thereby decreasing the incidence of acute and late adverse events, especially for larger CTV in case of WN-PORT.
There were several limitations to this study that should be acknowledged. First, this was a retrospective study conducted in a single center. Second, although PSM can reduce bias in causal estimates due to observed differences between treatment groups, there remains a risk of bias from unobserved differences. For example, WN-PORT had a different historical background from LF-PORT, as the former was adopted in 2011. Supportive care, including nutritional support and specialist care of the mouth, throat and skin during radiation therapy, had been improved year by year between 2000 and 2014. In addition, there was no information about the human papillomavirus (HPV) status of patients in this study. In the current era of interest in dose de-intensification of treatment for HPV-positive tumors, this series of LF-PORT vs. WN-PORT in patients with HPV-positive tumors might be interesting.
In conclusion, we performed PSM using a single institution cohort of patients with HNSCC to compare outcomes after LF-PORT and WN-PORT. WN-PORT was associated with statistically significant better LRC, PFS and OS. Although it is associated with an acceptable increase in the incidence of late toxicities of Grade 3 or higher, we recommended WN-PORT for treatment of advanced HNSCC, especially for cases with high-risk features.
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